This post from PharmaTech Talk discusses Lilly's exploration of new business models - spurred by this week's announcement that it is forming a new biotechnology company, called BioCritica, with private investors. BioCritica will focus on the development and commercialization of hospital-based, critical-care compounds including Lilly's Xigris for the treatment of severe sepsis. The company will also receive rights to acquire other compounds currently in prec-clinical development at Lilly.
PharmTech Talk » Eli Lilly’s New Biotech Company Builds on Alliance Strategy.
BioCritica is another model that Lilly is trying to help find an outlet for select products in its pipeline that might be better exploited by the alternative commercial strategy. It is a similar experiment to Lilly earlier this year committing $150 M to severall venture funds for early stage research and development. The arrangment is known as the Mirror Portfolio. Lilly continues to explore alternatives to its traditional model as it looks for novel ways to manage its pipeline and commercial portfolio to maximum effectiveness - with greater flexibility and better resource utilization.
Posted by Bruce Lehr May 24th 2011.
Comments